SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3o57'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1GSE_A_EAAA224_1 (GLUTATHIONE TRANSFERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	ARG A 203 LEU A 265 LEU A 334 VAL A 338 ALA A 272	None	0.99A	1gseA-3o57A: undetectable	1gseA-3o57A: 20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1QKU_A_ESTA600_1 (ESTRADIOL RECEPTOR)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 10	ALA A 391 LEU A 249 LEU A 250 MET A 196 ILE A 199	None	1.10A	1qkuA-3o57A: undetectable	1qkuA-3o57A: 20.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1QKU_B_ESTB600_1 (ESTRADIOL RECEPTOR)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 10	ALA A 391 LEU A 249 LEU A 250 MET A 196 ILE A 199	None	1.09A	1qkuB-3o57A: undetectable	1qkuB-3o57A: 20.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1QKU_C_ESTC600_1 (ESTRADIOL RECEPTOR)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 10	ALA A 391 LEU A 249 LEU A 250 MET A 196 ILE A 199	None	1.10A	1qkuC-3o57A: undetectable	1qkuC-3o57A: 20.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 10	TYR A 233 HIS A 234 PHE A 414 GLN A 443 GLY A 445 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.9A) ZG2 A 506 (-3.6A)	0.48A	1uhoA-3o57A: 36.2	1uhoA-3o57A: 28.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1WU8_C_ADNC502_1 (HYPOTHETICAL PROTEIN PH0463)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 7	PHE A 312 ASN A 305 ARG A 335 VAL A 342	None	1.29A	1wu8A-3o57A: undetectable 1wu8C-3o57A: undetectable	1wu8A-3o57A: 18.78 1wu8C-3o57A: 18.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 274 MET A 347 THR A 407 GLN A 443 PHE A 446	ZN A 1 (-3.3A) ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	1.47A	1xlxA-3o57A: 53.5	1xlxA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 HIS A 278 MET A 347 LEU A 393 ASN A 395 THR A 407 ILE A 410 MET A 411 SER A 442 GLN A 443 PHE A 446	None None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.55A	1xlxA-3o57A: 53.5	1xlxA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 274 MET A 347 THR A 407 GLN A 443 PHE A 446	ZN A 1 (-3.3A) ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	1.47A	1xlxB-3o57A: 53.5	1xlxB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 HIS A 278 MET A 347 THR A 407 ILE A 410 MET A 411 PHE A 414 MET A 431 GLN A 443 PHE A 446	None None None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.59A	1xlxB-3o57A: 53.5	1xlxB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 HIS A 278 MET A 347 THR A 407 ILE A 410 MET A 411 PHE A 414 MET A 431 SER A 442 PHE A 446	None None None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.70A	1xlxB-3o57A: 53.5	1xlxB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 ASP A 392 LEU A 393 PRO A 396 TYR A 403 TRP A 406 ILE A 410 PHE A 414 MET A 431 SER A 442 PHE A 446	None None ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.55A	1xmuA-3o57A: 54.3	1xmuA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 5	MET A 347 ASN A 395 THR A 407 MET A 411 GLN A 443	ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.3A) None ZG2 A 506 (-3.3A)	0.23A	1xmuA-3o57A: 54.3	1xmuA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TYR A 403 TRP A 406 ILE A 410 PHE A 414 MET A 431 SER A 442	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None	0.39A	1xmuB-3o57A: 53.6	1xmuB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_B_ROFB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 5	ASN A 395 THR A 407 MET A 411 GLN A 443 PHE A 446	ZG2 A 506 (-4.3A) ZG2 A 506 (-4.3A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.56A	1xmuB-3o57A: 53.6	1xmuB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 ILE A 410 MET A 411 PHE A 414 MET A 431 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.66A	1xomA-3o57A: 52.3	1xomA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 THR A 407 ILE A 410 MET A 411 MET A 431 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.64A	1xomB-3o57A: 51.9	1xomB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 THR A 407 ILE A 410 MET A 411 PHE A 414 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.59A	1xomB-3o57A: 51.9	1xomB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TYR A 403 THR A 407 ILE A 410 MET A 431 SER A 442 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.59A	1xoqA-3o57A: 52.2	1xoqA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ASN A 395 TRP A 406 GLN A 443	ZG2 A 506 (-4.3A) None ZG2 A 506 (-3.3A)	0.11A	1xoqA-3o57A: 52.2	1xoqA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 ASP A 392 LEU A 393 PRO A 396 TYR A 403 TRP A 406 THR A 407 ILE A 410 MET A 431 SER A 442 PHE A 446	None None ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.58A	1xoqB-3o57A: 51.8	1xoqB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	MET A 347 ASN A 395 GLN A 443	ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-3.3A)	0.29A	1xoqB-3o57A: 51.8	1xoqB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 MET A 411 PHE A 414 GLN A 443 PHE A 446 ILE A 450	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.52A	1xosA-3o57A: 53.2	1xosA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 MET A 411 PHE A 414 MET A 431 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.57A	1xosA-3o57A: 53.2	1xosA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	9 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 MET A 411 PHE A 414 SER A 429 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 (-4.4A) ARS A 3 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.91A	1xosA-3o57A: 53.2	1xosA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 ILE A 410 MET A 411 SER A 429 MET A 431 SER A 442 GLN A 443 PHE A 446 ILE A 450	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.4A) None ARS A 3 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.66A	1xotA-3o57A: 53.5	1xotA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 ASN A 395 ILE A 410 MET A 411 SER A 429 MET A 431 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ARS A 3 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.75A	1xotB-3o57A: 53.4	1xotB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 ASN A 395 ILE A 410 MET A 411 SER A 429 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ARS A 3 (-4.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.56A	1xotB-3o57A: 53.4	1xotB-3o57A: 93.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 PHE A 414 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.59A	2h42A-3o57A: 36.0	2h42A-3o57A: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	TYR A 233 LEU A 393 PHE A 414 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.60A	2h42C-3o57A: 35.7	2h42C-3o57A: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Q0J_B_BEZB500_0 (QUINOLONE SIGNAL RESPONSE PROTEIN)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	ASP A 275 HIS A 274 ASP A 392 LEU A 393 HIS A 238	MG A 504 ( 2.6A) ZN A 1 (-3.3A) ZN A 1 (-2.6A) None ZN A 1 (-3.3A)	1.30A	2q0jB-3o57A: undetectable	2q0jB-3o57A: 21.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	8 / 12	TYR A 233 HIS A 234 LEU A 393 ILE A 410 GLU A 413 PHE A 414 GLN A 443 PHE A 446	None None None ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.87A	2weyA-3o57A: 38.0	2weyA-3o57A: 27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 8	ILE A 410 PHE A 414 GLN A 443 PHE A 446	ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.47A	2weyB-3o57A: 37.8	2weyB-3o57A: 27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y69_P_CHDP1265_0 (CYTOCHROME C OXIDASE POLYPEPTIDE 7A1 CYTOCHROME C OXIDASE SUBUNIT 3)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 5	ARG A 331 PHE A 216 LEU A 315 PHE A 312	None	1.15A	2y69P-3o57A: 1.8 2y69W-3o57A: undetectable	2y69P-3o57A: 20.05 2y69W-3o57A: 11.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2YJA_B_ESTB1550_1 (ESTROGEN RECEPTOR)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	ALA A 391 LEU A 249 LEU A 250 MET A 196 ILE A 199	None	1.13A	2yjaB-3o57A: 2.8	2yjaB-3o57A: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AG3_C_CHDC271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE 7A1 CYTOCHROME C OXIDASE SUBUNIT 3)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 5	ARG A 331 PHE A 216 LEU A 315 PHE A 312	None	1.30A	3ag3C-3o57A: 1.8 3ag3J-3o57A: undetectable	3ag3C-3o57A: 20.05 3ag3J-3o57A: 8.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AG3_P_CHDP1271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE 7A1 CYTOCHROME C OXIDASE SUBUNIT 3)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 4	ARG A 331 PHE A 216 LEU A 315 PHE A 312	None	1.26A	3ag3P-3o57A: 1.8 3ag3W-3o57A: 0.0	3ag3P-3o57A: 20.05 3ag3W-3o57A: 8.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ARR_A_PNXA607_1 (CHITINASE A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 7	VAL A 242 SER A 394 THR A 246 LEU A 249	None	1.20A	3arrA-3o57A: undetectable	3arrA-3o57A: 20.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B2R_A_VDNA1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 12	TYR A 233 HIS A 234 LEU A 393 PHE A 414 GLN A 443 PHE A 446	None None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.62A	3b2rA-3o57A: 31.3	3b2rA-3o57A: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B2R_B_VDNB1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 LEU A 393 GLN A 443 PHE A 446	None None None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.61A	3b2rB-3o57A: 31.3	3b2rB-3o57A: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CZV_A_AZMA263_1 (CARBONIC ANHYDRASE 13)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 238 HIS A 274 PHE A 446 THR A 345 VAL A 451	ZN A 1 (-3.3A) ZN A 1 (-3.3A) ZG2 A 506 (-3.6A) MG A 504 ( 4.9A) None	1.21A	3czvA-3o57A: undetectable 3czvB-3o57A: undetectable	3czvA-3o57A: 21.27 3czvB-3o57A: 21.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_A_ROFA901_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASN A 395 PRO A 396 TYR A 403 TRP A 406 THR A 407 ILE A 410 MET A 431 SER A 442 PHE A 446	None None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.53A	3g4lA-3o57A: 51.6	3g4lA-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ASP A 392 LEU A 393 GLN A 443	ZN A 1 (-2.6A) None ZG2 A 506 (-3.3A)	0.27A	3g4lA-3o57A: 51.6	3g4lA-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TRP A 406 THR A 407 ILE A 410 MET A 411 MET A 431 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-3.4A) ZG2 A 506 (-3.6A)	0.50A	3g4lB-3o57A: 51.5	3g4lB-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 ASN A 395 PRO A 396 TYR A 403 TRP A 406 THR A 407 ILE A 410 MET A 431	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 (-4.3A) ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A)	0.33A	3g4lC-3o57A: 51.7	3g4lC-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	SER A 442 GLN A 443 PHE A 446	None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.43A	3g4lC-3o57A: 51.7	3g4lC-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TRP A 406 THR A 407 ILE A 410 MET A 411 SER A 442 GLN A 443	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None None ZG2 A 506 (-3.3A)	0.37A	3g4lD-3o57A: 52.2	3g4lD-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ASN A 395 MET A 431 PHE A 446	ZG2 A 506 (-4.3A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.6A)	0.68A	3g4lD-3o57A: 52.2	3g4lD-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 9	ILE A 410 MET A 431 GLN A 443 PHE A 446 ILE A 450	ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.81A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 9	MET A 347 ILE A 410 MET A 431 GLN A 443 PHE A 446	ZG2 A 506 (-3.9A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.95A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 9	TYR A 233 ASN A 395 ILE A 410 PHE A 414 GLN A 443 PHE A 446 ILE A 450	None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.52A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 9	TYR A 233 MET A 347 ASN A 395 ILE A 410 PHE A 414 GLN A 443 PHE A 446	None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.77A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IV6_D_SAMD301_0 (PUTATIVE ZN-DEPENDENT ALCOHOL DEHYDROGENASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	THR A 208 PHE A 216 SER A 213 ASP A 261 LEU A 265	None	1.03A	3iv6D-3o57A: undetectable	3iv6D-3o57A: 24.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 7	TYR A 233 HIS A 234 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.53A	3jwqC-3o57A: 39.1	3jwqC-3o57A: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 PHE A 414 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.58A	3jwqA-3o57A: 39.1 3jwqD-3o57A: 38.8	3jwqA-3o57A: 28.30 3jwqD-3o57A: 28.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 9	PRO A 396 THR A 407 ILE A 410 MET A 431 GLN A 443 PHE A 446	ZG2 A 506 ( 4.5A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.74A	3tvxA-3o57A: 52.8	3tvxA-3o57A: 86.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	8 / 9	TYR A 233 LEU A 393 ASN A 395 PRO A 396 THR A 407 ILE A 410 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.3A) ZG2 A 506 ( 4.5A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.40A	3tvxA-3o57A: 52.8	3tvxA-3o57A: 86.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 7	ASN A 395 ILE A 410 MET A 431 GLN A 443 PHE A 446	ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.88A	3tvxB-3o57A: 52.8	3tvxB-3o57A: 86.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 7	TYR A 233 ASN A 395 ILE A 410 PHE A 414 GLN A 443 PHE A 446	None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.51A	3tvxB-3o57A: 52.8	3tvxB-3o57A: 86.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WFH_B_P2EB301_1 (MAB FAB H FRAGMENT MAB FAB L FRAGMENT)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 307 VAL A 310 HIS A 278 PRO A 279 LEU A 293	None	1.33A	3wfhA-3o57A: undetectable 3wfhB-3o57A: undetectable	3wfhA-3o57A: 19.82 3wfhB-3o57A: 19.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WHX_B_XPGB301_1 (MAB FAB H FRAGMENT MAB FAB L FRAGMENT)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 307 VAL A 310 HIS A 278 PRO A 279 LEU A 293	None	1.31A	3whxA-3o57A: undetectable 3whxB-3o57A: undetectable	3whxA-3o57A: 18.91 3whxB-3o57A: 20.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4B7Q_C_ZMRC601_2 (NEURAMINIDASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ARG A 335 ARG A 331 ILE A 339	None	0.92A	4b7qC-3o57A: undetectable	4b7qC-3o57A: 20.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 6	ILE A 410 THR A 407 VAL A 281 ASP A 230	ZG2 A 506 (-4.4A) ZG2 A 506 (-4.3A) None None	1.09A	4iaqA-3o57A: undetectable	4iaqA-3o57A: 22.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XI3_D_29SD601_1 (ESTROGEN RECEPTOR)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	ALA A 391 TRP A 176 LEU A 249 LEU A 250 MET A 196	None	1.11A	4xi3D-3o57A: undetectable	4xi3D-3o57A: 20.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4Y03_A_SALA801_1 (PROTEIN POLYBROMO-1)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 7	ILE A 199 LEU A 192 ALA A 271 ILE A 268	None	0.76A	4y03A-3o57A: undetectable	4y03A-3o57A: 15.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5F8Y_A_X6XA202_1 (GALNAC/GAL-SPECIFIC LECTIN)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 8	GLU A 413 VAL A 231 HIS A 234 ASP A 275 HIS A 307	None None None MG A 504 ( 2.6A) None	1.19A	5f8yA-3o57A: undetectable	5f8yA-3o57A: 15.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5F8Y_B_X6XB201_1 (GALNAC/GAL-SPECIFIC LECTIN)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 8	GLU A 413 VAL A 231 HIS A 234 ASP A 275 HIS A 307	None None None MG A 504 ( 2.6A) None	1.21A	5f8yB-3o57A: undetectable	5f8yB-3o57A: 15.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_A_RAUA400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	LEU A 223 MET A 220 PHE A 216 MET A 196 GLY A 311	None	1.21A	5g6sA-3o57A: 0.6 5g6sG-3o57A: 0.3	5g6sA-3o57A: 22.73 5g6sG-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_A_RAUA400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	LEU A 223 MET A 220 TYR A 219 MET A 196 GLY A 311	None	0.90A	5g6sA-3o57A: 0.6 5g6sG-3o57A: 0.3	5g6sA-3o57A: 22.73 5g6sG-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_B_RAUB400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	LEU A 223 MET A 220 TYR A 219 MET A 196 GLY A 311	None	0.90A	5g6sB-3o57A: 0.5 5g6sC-3o57A: 0.5	5g6sB-3o57A: 22.73 5g6sC-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_C_RAUC400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	MET A 196 GLY A 311 LEU A 223 MET A 220 PHE A 216	None	1.21A	5g6sB-3o57A: undetectable 5g6sC-3o57A: undetectable	5g6sB-3o57A: 22.73 5g6sC-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_C_RAUC400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	MET A 196 GLY A 311 LEU A 223 MET A 220 TYR A 219	None	0.90A	5g6sB-3o57A: undetectable 5g6sC-3o57A: undetectable	5g6sB-3o57A: 22.73 5g6sC-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_D_RAUD400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 10	LEU A 223 MET A 220 PHE A 216 MET A 196 GLY A 311	None	1.21A	5g6sD-3o57A: 0.6 5g6sF-3o57A: 0.2	5g6sD-3o57A: 22.73 5g6sF-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_D_RAUD400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 10	LEU A 223 MET A 220 TYR A 219 MET A 196 GLY A 311	None	0.90A	5g6sD-3o57A: 0.6 5g6sF-3o57A: 0.2	5g6sD-3o57A: 22.73 5g6sF-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_E_RAUE400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	LEU A 223 MET A 220 PHE A 216 MET A 196 GLY A 311	None	1.22A	5g6sE-3o57A: 0.3 5g6sH-3o57A: 0.3	5g6sE-3o57A: 22.73 5g6sH-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5G6S_E_RAUE400_1 (IMINE REDUCTASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	LEU A 223 MET A 220 TYR A 219 MET A 196 GLY A 311	None	0.90A	5g6sE-3o57A: 0.3 5g6sH-3o57A: 0.3	5g6sE-3o57A: 22.73 5g6sH-3o57A: 22.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5GTR_A_ESTA601_1 (ESTROGEN RECEPTOR)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	ALA A 391 LEU A 249 LEU A 250 MET A 196 ILE A 199	None	1.08A	5gtrA-3o57A: 2.8	5gtrA-3o57A: 20.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5UAC_C_RFPC3001_1 (DNA-DIRECTED RNA POLYMERASE SUBUNIT BETA)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	GLN A 316 ASP A 277 HIS A 226 LEU A 315 ARG A 335	None	1.33A	5uacC-3o57A: 0.0	5uacC-3o57A: 12.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5WAU_C_CHDC308_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 5	ARG A 331 PHE A 216 LEU A 315 PHE A 312	None	1.26A	5wauc-3o57A: 1.8 5wauj-3o57A: undetectable	5wauc-3o57A: 20.05 5wauj-3o57A: 8.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5X1B_C_CHDC304_0 (CYTOCHROME C OXIDASE SUBUNIT 3)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ARG A 331 PHE A 216 LEU A 315	None	0.65A	5x1bC-3o57A: undetectable	5x1bC-3o57A: 20.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5XDQ_C_CHDC308_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 5	ARG A 331 PHE A 216 LEU A 315 PHE A 312	None	1.20A	5xdqC-3o57A: 1.8 5xdqJ-3o57A: undetectable	5xdqC-3o57A: 20.05 5xdqJ-3o57A: 8.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5XDQ_P_CHDP306_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 5	ARG A 331 PHE A 216 LEU A 315 PHE A 312	None	1.21A	5xdqP-3o57A: 1.8 5xdqW-3o57A: undetectable	5xdqP-3o57A: 20.05 5xdqW-3o57A: 8.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A93_B_8NUB3001_0 (5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	VAL A 371 THR A 367 LEU A 250 LEU A 384 VAL A 383	None	1.10A	6a93B-3o57A: undetectable	6a93B-3o57A: 21.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6NMP_C_CHDC307_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 6	ARG A 331 PHE A 216 LEU A 315 PHE A 312	None	1.34A	6nmpC-3o57A: undetectable 6nmpJ-3o57A: undetectable	6nmpC-3o57A: 20.05 6nmpJ-3o57A: 8.91

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1GSE_A_EAAA224_1","GLUTATHIONE TRANSFERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ARG A 203;LEU A 265;LEU A 334;VAL A 338;ALA A 272","None","0.99A","1gseA-3o57A:undetectable","1gseA-3o57A:20.98"],["1QKU_A_ESTA600_1","ESTRADIOL RECEPTOR","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ALA A 391;LEU A 249;LEU A 250;MET A 196;ILE A 199","None","1.10A","1qkuA-3o57A:undetectable","1qkuA-3o57A:20.71"],["1QKU_B_ESTB600_1","ESTRADIOL RECEPTOR","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ALA A 391;LEU A 249;LEU A 250;MET A 196;ILE A 199","None","1.09A","1qkuB-3o57A:undetectable","1qkuB-3o57A:20.71"],["1QKU_C_ESTC600_1","ESTRADIOL RECEPTOR","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ALA A 391;LEU A 249;LEU A 250;MET A 196;ILE A 199","None","1.10A","1qkuC-3o57A:undetectable","1qkuC-3o57A:20.71"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"TYR A 233;HIS A 234;PHE A 414;GLN A 443;GLY A 445;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.9A);ZG2 A 506 (-3.6A)","0.48A","1uhoA-3o57A:36.2","1uhoA-3o57A:28.03"],["1WU8_C_ADNC502_1","HYPOTHETICAL PROTEIN PH0463;HYPOTHETICAL PROTEIN PH0463","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"PHE A 312;ASN A 305;ARG A 335;VAL A 342","None","1.29A","1wu8A-3o57A:undetectable;1wu8C-3o57A:undetectable","1wu8A-3o57A:18.78;1wu8C-3o57A:18.78"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 274;MET A 347;THR A 407;GLN A 443;PHE A 446"," ZN A   1 (-3.3A);ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","1.47A","1xlxA-3o57A:53.5","1xlxA-3o57A:93.83"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;HIS A 278;MET A 347;LEU A 393;ASN A 395;THR A 407;ILE A 410;MET A 411;SER A 442;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.55A","1xlxA-3o57A:53.5","1xlxA-3o57A:93.83"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 274;MET A 347;THR A 407;GLN A 443;PHE A 446"," ZN A   1 (-3.3A);ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","1.47A","1xlxB-3o57A:53.5","1xlxB-3o57A:93.83"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;HIS A 278;MET A 347;THR A 407;ILE A 410;MET A 411;PHE A 414;MET A 431;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.59A","1xlxB-3o57A:53.5","1xlxB-3o57A:93.83"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;HIS A 278;MET A 347;THR A 407;ILE A 410;MET A 411;PHE A 414;MET A 431;SER A 442;PHE A 446","None;None;None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.70A","1xlxB-3o57A:53.5","1xlxB-3o57A:93.83"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;ASP A 392;LEU A 393;PRO A 396;TYR A 403;TRP A 406;ILE A 410;PHE A 414;MET A 431;SER A 442;PHE A 446","None;None; ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.55A","1xmuA-3o57A:54.3","1xmuA-3o57A:93.83"],["1XMU_A_ROFA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"MET A 347;ASN A 395;THR A 407;MET A 411;GLN A 443","ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.3A);None;ZG2 A 506 (-3.3A)","0.23A","1xmuA-3o57A:54.3","1xmuA-3o57A:93.83"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TYR A 403;TRP A 406;ILE A 410;PHE A 414;MET A 431;SER A 442","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None","0.39A","1xmuB-3o57A:53.6","1xmuB-3o57A:93.83"],["1XMU_B_ROFB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ASN A 395;THR A 407;MET A 411;GLN A 443;PHE A 446","ZG2 A 506 (-4.3A);ZG2 A 506 (-4.3A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.56A","1xmuB-3o57A:53.6","1xmuB-3o57A:93.83"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;ILE A 410;MET A 411;PHE A 414;MET A 431;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.66A","1xomA-3o57A:52.3","1xomA-3o57A:82.81"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;MET A 347;LEU A 393;THR A 407;ILE A 410;MET A 411;MET A 431;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.64A","1xomB-3o57A:51.9","1xomB-3o57A:82.81"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;MET A 347;LEU A 393;THR A 407;ILE A 410;MET A 411;PHE A 414;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.59A","1xomB-3o57A:51.9","1xomB-3o57A:82.81"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TYR A 403;THR A 407;ILE A 410;MET A 431;SER A 442;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.59A","1xoqA-3o57A:52.2","1xoqA-3o57A:82.81"],["1XOQ_A_ROFA502_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ASN A 395;TRP A 406;GLN A 443","ZG2 A 506 (-4.3A);None;ZG2 A 506 (-3.3A)","0.11A","1xoqA-3o57A:52.2","1xoqA-3o57A:82.81"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;ASP A 392;LEU A 393;PRO A 396;TYR A 403;TRP A 406;THR A 407;ILE A 410;MET A 431;SER A 442;PHE A 446","None;None; ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.58A","1xoqB-3o57A:51.8","1xoqB-3o57A:82.81"],["1XOQ_B_ROFB501_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"MET A 347;ASN A 395;GLN A 443","ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-3.3A)","0.29A","1xoqB-3o57A:51.8","1xoqB-3o57A:82.81"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",10,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;MET A 411;PHE A 414;GLN A 443;PHE A 446;ILE A 450","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.52A","1xosA-3o57A:53.2","1xosA-3o57A:93.83"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",10,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;MET A 411;PHE A 414;MET A 431;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.57A","1xosA-3o57A:53.2","1xosA-3o57A:93.83"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",9,"TYR A 233;HIS A 234;MET A 347;ASP A 392;MET A 411;PHE A 414;SER A 429;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 (-4.4A);ARS A   3 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.91A","1xosA-3o57A:53.2","1xosA-3o57A:93.83"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;LEU A 393;ILE A 410;MET A 411;SER A 429;MET A 431;SER A 442;GLN A 443;PHE A 446;ILE A 450","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.4A);None;ARS A   3 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.66A","1xotA-3o57A:53.5","1xotA-3o57A:93.83"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",10,"TYR A 233;HIS A 234;ASN A 395;ILE A 410;MET A 411;SER A 429;MET A 431;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ARS A   3 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.75A","1xotB-3o57A:53.4","1xotB-3o57A:93.83"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;MET A 347;LEU A 393;ASN A 395;ILE A 410;MET A 411;SER A 429;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ARS A   3 (-4.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.56A","1xotB-3o57A:53.4","1xotB-3o57A:93.83"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;HIS A 234;PHE A 414;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.59A","2h42A-3o57A:36.0","2h42A-3o57A:27.53"],["2H42_C_VIAC903_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;LEU A 393;PHE A 414;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.60A","2h42C-3o57A:35.7","2h42C-3o57A:27.53"],["2Q0J_B_BEZB500_0","QUINOLONE SIGNAL RESPONSE PROTEIN","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ASP A 275;HIS A 274;ASP A 392;LEU A 393;HIS A 238"," MG A 504 ( 2.6A); ZN A   1 (-3.3A); ZN A   1 (-2.6A);None; ZN A   1 (-3.3A)","1.30A","2q0jB-3o57A:undetectable","2q0jB-3o57A:21.09"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",8,"TYR A 233;HIS A 234;LEU A 393;ILE A 410;GLU A 413;PHE A 414;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.87A","2weyA-3o57A:38.0","2weyA-3o57A:27.20"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ILE A 410;PHE A 414;GLN A 443;PHE A 446","ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.47A","2weyB-3o57A:37.8","2weyB-3o57A:27.20"],["2Y69_P_CHDP1265_0","CYTOCHROME C OXIDASE POLYPEPTIDE 7A1;CYTOCHROME C OXIDASE SUBUNIT 3","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ARG A 331;PHE A 216;LEU A 315;PHE A 312","None","1.15A","2y69P-3o57A:1.8;2y69W-3o57A:undetectable","2y69P-3o57A:20.05;2y69W-3o57A:11.05"],["2YJA_B_ESTB1550_1","ESTROGEN RECEPTOR","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ALA A 391;LEU A 249;LEU A 250;MET A 196;ILE A 199","None","1.13A","2yjaB-3o57A:2.8","2yjaB-3o57A:21.47"],["3AG3_C_CHDC271_0","CYTOCHROME C OXIDASE POLYPEPTIDE 7A1;CYTOCHROME C OXIDASE SUBUNIT 3","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ARG A 331;PHE A 216;LEU A 315;PHE A 312","None","1.30A","3ag3C-3o57A:1.8;3ag3J-3o57A:undetectable","3ag3C-3o57A:20.05;3ag3J-3o57A:8.91"],["3AG3_P_CHDP1271_0","CYTOCHROME C OXIDASE POLYPEPTIDE 7A1;CYTOCHROME C OXIDASE SUBUNIT 3","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ARG A 331;PHE A 216;LEU A 315;PHE A 312","None","1.26A","3ag3P-3o57A:1.8;3ag3W-3o57A:0.0","3ag3P-3o57A:20.05;3ag3W-3o57A:8.91"],["3ARR_A_PNXA607_1","CHITINASE A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"VAL A 242;SER A 394;THR A 246;LEU A 249","None","1.20A","3arrA-3o57A:undetectable","3arrA-3o57A:20.83"],["3B2R_A_VDNA1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"TYR A 233;HIS A 234;LEU A 393;PHE A 414;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.62A","3b2rA-3o57A:31.3","3b2rA-3o57A:28.57"],["3B2R_B_VDNB1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;HIS A 234;LEU A 393;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.61A","3b2rB-3o57A:31.3","3b2rB-3o57A:28.57"],["3CZV_A_AZMA263_1","CARBONIC ANHYDRASE 13;CARBONIC ANHYDRASE 13","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 238;HIS A 274;PHE A 446;THR A 345;VAL A 451"," ZN A   1 (-3.3A); ZN A   1 (-3.3A);ZG2 A 506 (-3.6A); MG A 504 ( 4.9A);None","1.21A","3czvA-3o57A:undetectable;3czvB-3o57A:undetectable","3czvA-3o57A:21.27;3czvB-3o57A:21.27"],["3G4L_A_ROFA901_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASN A 395;PRO A 396;TYR A 403;TRP A 406;THR A 407;ILE A 410;MET A 431;SER A 442;PHE A 446","None;None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.53A","3g4lA-3o57A:51.6","3g4lA-3o57A:80.37"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ASP A 392;LEU A 393;GLN A 443"," ZN A   1 (-2.6A);None;ZG2 A 506 (-3.3A)","0.27A","3g4lA-3o57A:51.6","3g4lA-3o57A:80.37"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TRP A 406;THR A 407;ILE A 410;MET A 411;MET A 431;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-3.4A);ZG2 A 506 (-3.6A)","0.50A","3g4lB-3o57A:51.5","3g4lB-3o57A:80.37"],["3G4L_C_ROFC903_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;ASN A 395;PRO A 396;TYR A 403;TRP A 406;THR A 407;ILE A 410;MET A 431","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 (-4.3A);ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A)","0.33A","3g4lC-3o57A:51.7","3g4lC-3o57A:80.37"],["3G4L_C_ROFC903_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"SER A 442;GLN A 443;PHE A 446","None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.43A","3g4lC-3o57A:51.7","3g4lC-3o57A:80.37"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TRP A 406;THR A 407;ILE A 410;MET A 411;SER A 442;GLN A 443","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;None;ZG2 A 506 (-3.3A)","0.37A","3g4lD-3o57A:52.2","3g4lD-3o57A:80.37"],["3G4L_D_ROFD904_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ASN A 395;MET A 431;PHE A 446","ZG2 A 506 (-4.3A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.6A)","0.68A","3g4lD-3o57A:52.2","3g4lD-3o57A:80.37"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ILE A 410;MET A 431;GLN A 443;PHE A 446;ILE A 450","ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.81A","3iakA-3o57A:51.2","3iakA-3o57A:82.81"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"MET A 347;ILE A 410;MET A 431;GLN A 443;PHE A 446","ZG2 A 506 (-3.9A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.95A","3iakA-3o57A:51.2","3iakA-3o57A:82.81"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",7,"TYR A 233;ASN A 395;ILE A 410;PHE A 414;GLN A 443;PHE A 446;ILE A 450","None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.52A","3iakA-3o57A:51.2","3iakA-3o57A:82.81"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",7,"TYR A 233;MET A 347;ASN A 395;ILE A 410;PHE A 414;GLN A 443;PHE A 446","None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.77A","3iakA-3o57A:51.2","3iakA-3o57A:82.81"],["3IV6_D_SAMD301_0","PUTATIVE ZN-DEPENDENT ALCOHOL DEHYDROGENASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"THR A 208;PHE A 216;SER A 213;ASP A 261;LEU A 265","None","1.03A","3iv6D-3o57A:undetectable","3iv6D-3o57A:24.17"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"TYR A 233;HIS A 234;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.53A","3jwqC-3o57A:39.1","3jwqC-3o57A:28.30"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;HIS A 234;PHE A 414;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.58A","3jwqA-3o57A:39.1;3jwqD-3o57A:38.8","3jwqA-3o57A:28.30;3jwqD-3o57A:28.30"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"PRO A 396;THR A 407;ILE A 410;MET A 431;GLN A 443;PHE A 446","ZG2 A 506 ( 4.5A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.74A","3tvxA-3o57A:52.8","3tvxA-3o57A:86.83"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",8,"TYR A 233;LEU A 393;ASN A 395;PRO A 396;THR A 407;ILE A 410;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.3A);ZG2 A 506 ( 4.5A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.40A","3tvxA-3o57A:52.8","3tvxA-3o57A:86.83"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ASN A 395;ILE A 410;MET A 431;GLN A 443;PHE A 446","ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.88A","3tvxB-3o57A:52.8","3tvxB-3o57A:86.83"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"TYR A 233;ASN A 395;ILE A 410;PHE A 414;GLN A 443;PHE A 446","None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.51A","3tvxB-3o57A:52.8","3tvxB-3o57A:86.83"],["3WFH_B_P2EB301_1","MAB FAB H FRAGMENT;MAB FAB L FRAGMENT","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 307;VAL A 310;HIS A 278;PRO A 279;LEU A 293","None","1.33A","3wfhA-3o57A:undetectable;3wfhB-3o57A:undetectable","3wfhA-3o57A:19.82;3wfhB-3o57A:19.55"],["3WHX_B_XPGB301_1","MAB FAB H FRAGMENT;MAB FAB L FRAGMENT","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 307;VAL A 310;HIS A 278;PRO A 279;LEU A 293","None","1.31A","3whxA-3o57A:undetectable;3whxB-3o57A:undetectable","3whxA-3o57A:18.91;3whxB-3o57A:20.66"],["4B7Q_C_ZMRC601_2","NEURAMINIDASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ARG A 335;ARG A 331;ILE A 339","None","0.92A","4b7qC-3o57A:undetectable","4b7qC-3o57A:20.29"],["4IAQ_A_2GMA2001_2","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ILE A 410;THR A 407;VAL A 281;ASP A 230","ZG2 A 506 (-4.4A);ZG2 A 506 (-4.3A);None;None","1.09A","4iaqA-3o57A:undetectable","4iaqA-3o57A:22.90"],["4XI3_D_29SD601_1","ESTROGEN RECEPTOR","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ALA A 391;TRP A 176;LEU A 249;LEU A 250;MET A 196","None","1.11A","4xi3D-3o57A:undetectable","4xi3D-3o57A:20.92"],["4Y03_A_SALA801_1","PROTEIN POLYBROMO-1","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ILE A 199;LEU A 192;ALA A 271;ILE A 268","None","0.76A","4y03A-3o57A:undetectable","4y03A-3o57A:15.86"],["5F8Y_A_X6XA202_1","GALNAC\/GAL-SPECIFIC LECTIN","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"GLU A 413;VAL A 231;HIS A 234;ASP A 275;HIS A 307","None;None;None; MG A 504 ( 2.6A);None","1.19A","5f8yA-3o57A:undetectable","5f8yA-3o57A:15.58"],["5F8Y_B_X6XB201_1","GALNAC\/GAL-SPECIFIC LECTIN","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"GLU A 413;VAL A 231;HIS A 234;ASP A 275;HIS A 307","None;None;None; MG A 504 ( 2.6A);None","1.21A","5f8yB-3o57A:undetectable","5f8yB-3o57A:15.58"],["5G6S_A_RAUA400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"LEU A 223;MET A 220;PHE A 216;MET A 196;GLY A 311","None","1.21A","5g6sA-3o57A:0.6;5g6sG-3o57A:0.3","5g6sA-3o57A:22.73;5g6sG-3o57A:22.73"],["5G6S_A_RAUA400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"LEU A 223;MET A 220;TYR A 219;MET A 196;GLY A 311","None","0.90A","5g6sA-3o57A:0.6;5g6sG-3o57A:0.3","5g6sA-3o57A:22.73;5g6sG-3o57A:22.73"],["5G6S_B_RAUB400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"LEU A 223;MET A 220;TYR A 219;MET A 196;GLY A 311","None","0.90A","5g6sB-3o57A:0.5;5g6sC-3o57A:0.5","5g6sB-3o57A:22.73;5g6sC-3o57A:22.73"],["5G6S_C_RAUC400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"MET A 196;GLY A 311;LEU A 223;MET A 220;PHE A 216","None","1.21A","5g6sB-3o57A:undetectable;5g6sC-3o57A:undetectable","5g6sB-3o57A:22.73;5g6sC-3o57A:22.73"],["5G6S_C_RAUC400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"MET A 196;GLY A 311;LEU A 223;MET A 220;TYR A 219","None","0.90A","5g6sB-3o57A:undetectable;5g6sC-3o57A:undetectable","5g6sB-3o57A:22.73;5g6sC-3o57A:22.73"],["5G6S_D_RAUD400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"LEU A 223;MET A 220;PHE A 216;MET A 196;GLY A 311","None","1.21A","5g6sD-3o57A:0.6;5g6sF-3o57A:0.2","5g6sD-3o57A:22.73;5g6sF-3o57A:22.73"],["5G6S_D_RAUD400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"LEU A 223;MET A 220;TYR A 219;MET A 196;GLY A 311","None","0.90A","5g6sD-3o57A:0.6;5g6sF-3o57A:0.2","5g6sD-3o57A:22.73;5g6sF-3o57A:22.73"],["5G6S_E_RAUE400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"LEU A 223;MET A 220;PHE A 216;MET A 196;GLY A 311","None","1.22A","5g6sE-3o57A:0.3;5g6sH-3o57A:0.3","5g6sE-3o57A:22.73;5g6sH-3o57A:22.73"],["5G6S_E_RAUE400_1","IMINE REDUCTASE;IMINE REDUCTASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"LEU A 223;MET A 220;TYR A 219;MET A 196;GLY A 311","None","0.90A","5g6sE-3o57A:0.3;5g6sH-3o57A:0.3","5g6sE-3o57A:22.73;5g6sH-3o57A:22.73"],["5GTR_A_ESTA601_1","ESTROGEN RECEPTOR","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ALA A 391;LEU A 249;LEU A 250;MET A 196;ILE A 199","None","1.08A","5gtrA-3o57A:2.8","5gtrA-3o57A:20.44"],["5UAC_C_RFPC3001_1","DNA-DIRECTED RNA POLYMERASE SUBUNIT BETA","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"GLN A 316;ASP A 277;HIS A 226;LEU A 315;ARG A 335","None","1.33A","5uacC-3o57A:0.0","5uacC-3o57A:12.99"],["5WAU_C_CHDC308_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ARG A 331;PHE A 216;LEU A 315;PHE A 312","None","1.26A","5wauc-3o57A:1.8;5wauj-3o57A:undetectable","5wauc-3o57A:20.05;5wauj-3o57A:8.91"],["5X1B_C_CHDC304_0","CYTOCHROME C OXIDASE SUBUNIT 3","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ARG A 331;PHE A 216;LEU A 315","None","0.65A","5x1bC-3o57A:undetectable","5x1bC-3o57A:20.05"],["5XDQ_C_CHDC308_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ARG A 331;PHE A 216;LEU A 315;PHE A 312","None","1.20A","5xdqC-3o57A:1.8;5xdqJ-3o57A:undetectable","5xdqC-3o57A:20.05;5xdqJ-3o57A:8.91"],["5XDQ_P_CHDP306_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ARG A 331;PHE A 216;LEU A 315;PHE A 312","None","1.21A","5xdqP-3o57A:1.8;5xdqW-3o57A:undetectable","5xdqP-3o57A:20.05;5xdqW-3o57A:8.91"],["6A93_B_8NUB3001_0","5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"VAL A 371;THR A 367;LEU A 250;LEU A 384;VAL A 383","None","1.10A","6a93B-3o57A:undetectable","6a93B-3o57A:21.61"],["6NMP_C_CHDC307_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ARG A 331;PHE A 216;LEU A 315;PHE A 312","None","1.34A","6nmpC-3o57A:undetectable;6nmpJ-3o57A:undetectable","6nmpC-3o57A:20.05;6nmpJ-3o57A:8.91"]]